HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Paula R PohlmannDeena GrahamTianmin WuYvonne OttavianoMahsa MohebtashShweta KurianDonna McNamaraFilipa C LynceRobert WarrenAsma DilawariSuman RaoCandace MainorNicole SwansonMing T TanClaudine IsaacsSandra M SwainPublished in: Breast cancer research and treatment (2022)
Clinicaltrials.gov, NCT02910219, prospectively registered September 21, 2016.
Keyphrases
- phase ii study
- positive breast cancer
- chemotherapy induced
- metastatic breast cancer
- open label
- epidermal growth factor receptor
- phase ii
- phase iii
- clinical trial
- irritable bowel syndrome
- locally advanced
- study protocol
- clostridium difficile
- tyrosine kinase
- randomized controlled trial
- placebo controlled
- radiation therapy
- rectal cancer